Trial Profile

Open Label Phase 1/2 Trial of Tisotumab Vedotin in Japanese Subjects With Advanced Solid Malignancies

Status: Discontinued

Phase of Trial: Phase I/II

Latest Information Update: 08 Dec 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tisotumab-vedotin (Primary)
Indications Adenocarcinoma; Cervical cancer; Solid tumours; Squamous cell cancer
Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
Acronyms innovaTV 206
Sponsors Genmab

Most Recent Events

06 Dec 2022 Status changed from completed to discontinued.
01 Aug 2022 Results published in the Cancer Science
02 Dec 2021 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com